Truist analyst Gregory Renza raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $38 from $32 and keeps a Buy rating on the shares after Tuesday night’s approval of Aqvesme for patients with NTD and TD alpha-/beta-thalassemia. The firm called Aqvesme’s approval in thalassemia “expected but still a relief,” in spite of the PDUFA delay.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Here’s Why Agios Stock (AGIO) Is Suddenly on the Rise Today
- Agios Pharmaceuticals’ Aqvesme to be introduced at $425K per patient per year
- Agios Pharmaceuticals price target raised to $34 from $32 at BofA
- FDA approves Agios Pharmaceuticals’ Aqvesme in anemia patients
- Agios Pharmaceuticals trading halted, news pending